SERA Stock Overview
Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Sera Prognostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.40 |
| 52 Week High | US$7.29 |
| 52 Week Low | US$1.10 |
| Beta | 0 |
| 1 Month Change | 1.45% |
| 3 Month Change | 3.70% |
| 1 Year Change | -80.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.24% |
Recent News & Updates
Recent updates
We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Nov 03
A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening
Aug 10We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Jul 21Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation
Apr 06We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely
Dec 15Shareholder Returns
| SERA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.5% | -0.8% | 1.7% |
| 1Y | -80.1% | 4.4% | -9.6% |
Return vs Industry: SERA underperformed the US Biotechs industry which returned 4.4% over the past year.
Return vs Market: SERA underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| SERA volatility | |
|---|---|
| SERA Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SERA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: SERA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 114 | Greg Critchfield | https://seraprognostics.com |
Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.
Sera Prognostics, Inc. Fundamentals Summary
| SERA fundamental statistics | |
|---|---|
| Market Cap | US$43.42m |
| Earnings (TTM) | -US$46.92m |
| Revenue (TTM) | US$229.00k |
189.6x
P/S Ratio-0.9x
P/E RatioIs SERA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SERA income statement (TTM) | |
|---|---|
| Revenue | US$229.00k |
| Cost of Revenue | US$148.00k |
| Gross Profit | US$81.00k |
| Other Expenses | US$47.01m |
| Earnings | -US$46.92m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 35.37% |
| Net Profit Margin | -20,490.83% |
| Debt/Equity Ratio | 0% |
How did SERA perform over the long term?
See historical performance and comparison